KUALA LUMPUR, March 11 -- Crown Bioscience has launched two new liver fibrosis rodent models, allowing more rapid and cost-effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis and/or fibrosis reversal.
The launch of these models furthers CrownBio’s commitment to progressing NASH drug development by providing a wider breadth of preclinical platforms.
According to a statement, the two models encompass fibrosis induced by carbon tetrachloride and a new cholesterol-added, choline-deficient fibrosis (CCDF) diet.
The new CCDF diet is a modification of the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) currently in preclinical use, featuring lower fat composition and added cholesterol.
The resulting Wistar rat and C57BL/6 murine models display more severe liver injury than rodents on CDAHFD, with fibrosis observed in only six to nine weeks, and without the significant weight loss commonly observed in conventional chemical and nutritional deficit models.
“Fibrosis is associated with more severe forms of NASH, so developing new platforms to model this disease aspect can help the patient populations worst affected by this silent disease,” said CrownBio senior vice-president (Cardiovascular and Metabolic Disease), Dr Jim Wang.
“These new models, along with other liver disease models including MS-NASH and CCl(4) induced or modified rodent models, as well as NHP models, add to our vision of establishing a market-leading platform of highly translational models to accelerate NASH drug discovery.”
-- BERNAMA
No comments:
Post a Comment